Cabaletta Bio (CABA) Return on Capital Employed (2019 - 2026)
Cabaletta Bio (CABA) posted quarterly Return on Capital Employed of 135.34% for Q4 2025, down 6069.0% year-over-year from 2.27% in Q4 2024, and down 33.66% quarter-over-quarter from 101.25% in Q3 2025.
Cabaletta Bio (CABA) Return on Capital Employed (2019 - 2026) Analysis & Trends
Cabaletta Bio's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 135.34% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 6069.0% year-over-year to 135.34%; the TTM figure through Dec 2025 stood at 135.34% (down 6069.0% YoY), while the FY2025 annual figure was 137.89%, down 7280.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 135.34%, down from 101.25% in the prior quarter.
- The five-year high for Return on Capital Employed was 33.31% in Q1 2021, with the low at 135.34% in Q4 2025.
- The 5-year median for Return on Capital Employed is 49.14% (2024), against an average of 59.44%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 2015 bps in 2024, then plunged 6069 bps in 2025.
- Cabaletta Bio's Return on Capital Employed stood at 39.89% in 2021, then sank by 43 bps to 57.09% in 2022, then jumped by 34 bps to 37.81% in 2023, then tumbled by 97 bps to 74.65% in 2024, then slumped by 81 bps to 135.34% in 2025.
- Business Quant data shows CABA's Return on Capital Employed at 135.34% in Q4 2025, 101.25% in Q3 2025, and 97.78% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | -109.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -109.43% |
| Dec 31, 2025 | -135.34% |
| Sep 30, 2025 | -101.25% |
| Jun 30, 2025 | -97.78% |
| Mar 31, 2025 | -95.14% |
| Dec 31, 2024 | -74.65% |
| Sep 30, 2024 | -60.89% |
| Jun 30, 2024 | -47.44% |
| Mar 31, 2024 | -37.43% |
| Dec 31, 2023 | -37.81% |
| Sep 30, 2023 | -40.28% |
| Jun 30, 2023 | -44.94% |
| Mar 31, 2023 | -57.58% |
| Dec 31, 2022 | -57.09% |
| Sep 30, 2022 | -56.82% |
| Jun 30, 2022 | -50.83% |
| Mar 31, 2022 | -43.87% |
| Dec 31, 2021 | -39.89% |
| Sep 30, 2021 | -38.39% |
| Jun 30, 2021 | -38.03% |